Top Tweets for #CS2009

about 1 year ago

🇨🇳 #CStone Pharma announced today that the global multicenter Phase I/II study of #CS2009, a potential first-in-class/best-in-class PD-1/VEGF/CTLA-4 #trispecific #antibody independently developed by CStone, is actively enrolling patients in Australia and China, with planned expansion to the United States for Phase II enrollment. https://t.co/0D7auwpypq Recently, a PCT patent of 🇨🇳 #Zelgen's PD-L1/VEGF/CCR8 trispecific antibody (WO2025140619). To date, 4 PD-1(L1)/VEGF trispecific antibody drugs have entered clinical trials, including 2 PD-1/VEGF/CTLA-4 antibodies and 2 PD-L1/VEGF/TGFβ antibodies. (Source: UmabsDB) PD-1/VEGF/CTLA-4: -HC 010 (🇨🇳 HC Biopharma, Ph1) -CS 2009 (🇨🇳 CStone, Ph1) -GB 268 (🇨🇳Genor Biopharma, IND submission) PD-L1/VEGF/TGFβ -PM8003 (🇨🇳 Biotheus, Ph1 discontinued) -DR30206 (🇨🇳 Doer Biologics, Ph1) -Q 1806 (🇨🇳 QureBio, Preclinical) PD-L1/VEGF/HER2 -(🇨🇳 Sanyou Bio, patent public) PD-L1/VEGF/CCR8 -(🇨🇳 Zelgen, patent public)

Minhua Chu

@chuminhua432

over 1 year ago

🇨🇳 #CStone announced that the first patient has been successfully dosed in the global multicenter Ph1 clinical trial of its novel PD-1/VEGF/CTLA-4 trispecific antibody, #CS2009, with no infusion reactions or other adverse events observed. https://t.co/OE83g5aueB

741

Minhua Chu

@chuminhua432

over 1 year ago

🇨🇳 #CStone registered a ph1 study for #CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, in Participants with Advanced Solid Tumors https://t.co/1M7m3ylmLC

ℛℴ𝓈𝓎 𝒮𝒶𝓃𝒸𝒽ℯ𝓏 ✨ @Rouszii

over 11 years ago

@Yanezwebspain Me fascina ver #CS2009, @LaloYanezLue va mas allá de un simple personaje, transmite sentimientos a flor de piel, excelente ..

ℛℴ𝓈𝓎 𝒮𝒶𝓃𝒸𝒽ℯ𝓏 ✨ @Rouszii

almost 12 years ago

@6359Madrid @TeamYanezUSA acepto reto nomino @luciaperedagar @Ana3261Ana @merilui66 #JuandelDiablo #CS2009

Top Tweets for #CS2009

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users